MannKind Corporation (MNKD)
NASDAQ: MNKD · IEX Real-Time Price · USD
4.340
+0.230 (5.60%)
May 1, 2024, 4:00 PM EDT - Market closed
MannKind Revenue
In the year 2023, MannKind had annual revenue of $198.96M with 99.42% growth. Revenue in the quarter ending December 31, 2023 was $58.47M with 62.16% year-over-year growth.
Revenue (ttm)
$198.96M
Revenue Growth
+99.42%
P/S Ratio
5.90
Revenue / Employee
$484,092
Employees
411
Market Cap
1.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
Dec 31, 2016 | 174.76M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 35.00K | -15.00K | -30.00% |
Dec 31, 2011 | 50.00K | -43.00K | -46.24% |
Dec 31, 2010 | 93.00K | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 20.00K | 10.00K | 100.00% |
Dec 31, 2007 | 10.00K | -90.00K | -90.00% |
Dec 31, 2006 | 100.00K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 326.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Collegium Pharmaceutical | 566.77M |
AtriCure | 399.25M |
Phreesia | 356.30M |
Maravai LifeSciences Holdings | 288.95M |
Mirum Pharmaceuticals | 186.37M |
Prothena Corporation | 91.37M |
Vir Biotechnology | 86.18M |
AbCellera Biologics | 38.03M |
MNKD News
- 10 hours ago - MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 - GlobeNewsWire
- 1 day ago - MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases - GlobeNewsWire
- 2 days ago - MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease - GlobeNewsWire
- 4 weeks ago - MannKind Repays Certain Debt Obligations - GlobeNewsWire
- 5 weeks ago - MannKind Announces CFO Transition - GlobeNewsWire
- 7 weeks ago - INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps - GlobeNewsWire
- 2 months ago - MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 - GlobeNewsWire
- 2 months ago - MannKind Corporation Announces Participation at Upcoming Conferences - GlobeNewsWire